Logo

Ferrer, Oryzon to Co-Develop Genomic, Proteomic Tools for Colorectal Cancer

Apr 04, 2005

NEW YORK, April 4 (GenomeWeb News) - Ferrer International and Oryzon Genomics have formed a collaboration to develop new genomic- and proteomic-based products for the early diagnosis and prognosis of colorectal cancer, the firms said yesterday.

 

According to the Spanish companies, their partnership will include the genomic and proteomic analysis of hundreds of tumor samples in order to uncover clues about colorectal cancer and how to improve molecular tools for diagnosis and prognosis of the disease.

 

The initial research portion of the collaboration is expected to last two years, and will require an investment of almost €1 million, the companies said. The effort is being supported by the Catalan Institute of Oncology and the College Hospital Vall d'Hebron, they added.

Breaking News
The Scan

Researchers Compare WGS, Exome Sequencing-Based Mendelian Disease Diagnosis

Investigators find a diagnostic edge for whole-genome sequencing, while highlighting the cost advantages and improving diagnostic rate of exome sequencing in EJHG.

Researchers Retrace Key Mutations in Reassorted H1N1 Swine Flu Virus With Avian-Like Features

Mutations in the acidic polymerase-coding gene boost the pathogenicity and transmissibility of Eurasian avian-like H1N1 swine influenza viruses, a PNAS paper finds.

Genome Sequences Reveal Evolutionary History of South America's Canids

An analysis in PNAS of South American canid species' genomes offers a look at their evolutionary history, as well as their relationships and adaptations.

Lung Cancer Response to Checkpoint Inhibitors Reflected in Circulating Tumor DNA

In non-small cell lung cancer patients, researchers find in JCO Precision Oncology that survival benefits after immune checkpoint blockade coincide with a dip in ctDNA levels.